Assessing risk of COVID-19 reinfection and complications in adults treated with stimulant medications: A retrospective study using electronic health records Risk of COVID-19 reinfection and complications in adults prescribed stimulants

Article Sidebar

6-Oct-5807.pdf
Published Sep 30, 2024
DOI: https://doi.org/10.18103/mra.v12i9.5807

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Wen-Jan Tuan, DHA
Departments of Family and Community Medicine and Public Health Science, College of Medicine, Pennsylvania State University
http://orcid.org/0000-0003-3939-8979 Adriana Von Rago
College of Medicine, Pennsylvania State University, Pennsylvania, USA
http://orcid.org/0009-0002-8027-0838 Christopher Heron, MD
Department of Family and Community Medicine, College of Medicine, Pennsylvania State University, Pennsylvania, USA
http://orcid.org/0000-0002-8245-2953 Michael Partin, MD
Department of Family and Community Medicine, College of Medicine, Pennsylvania State University, Pennsylvania, USA
Kyle Burke, MD
Departments of Family and Community Medicine, Pennsylvania State University, Pennsylvania, USA
http://orcid.org/0009-0006-6322-8995 Grace Hwang http://orcid.org/0009-0008-3610-5214 Aleksandra E. Zgierska, MD, PhD http://orcid.org/0000-0002-7773-6003

Abstract

Despite advancement in vaccines and treatments for COVID-19 over time, many concerns remain about reinfection and waning immunity against COVID-19 and its variants, including among individuals treated with stimulants. The study aimed to evaluate the risk of COVID-19 reinfection and severe illness among adults prescribed stimulants compared to those not on stimulant therapy to elucidate the potential relationship of this therapy to the COVID-19 reinfection-related outcomes. A retrospective cohort study was conducted using the TriNetX database consisting of over 2,563,130 adults (age ≥18 years) with COVID-19 infection from January 1, 2020 to April 30, 2022. COVID-19 reinfection was defined as a new COVID-19 illness documented ≥ 30 days after the initial infection. Logistic regression was applied to assess the odds ratios (ORs) of COVID-19 reinfection and severe illness course (presence of emergence department (ED), hospitalization, and intensive care unit (ICU) care, mortality) within 30 days of reinfection, controlled for demographic and comorbid condition characteristics. Analysis revealed that adults who received at least three prescriptions for stimulants, compared to those without any stimulant prescriptions within six months prior to the initial COVID-19 illness, were more likely to be re-infected by COVID-19 (aOR=1.36, 95% confidence interval (CI): 1.32-1.41), but less likely to be treated in the ED (aOR=0.77, 95% CI: 0.72-0.82), hospital (aOR=0.72, 95% CI: 0.63-0.82), ICU (aOR=0.68, 95% CI: 0.53-0.89), or die (aOR=0.31, 95% CI: 0.15-0.64) within 30 days of reinfection (all p-values < 0.01). The study offers additional insights into the potential risks and benefits of prescription stimulants to aid in clinical decision making for treating COVID-19 reinfection in adults on stimulant therapy.

Keywords: Prescription stimulant, COVID-19 reinfection, COVID-19 outcome

Article Details

How to Cite
TUAN, Wen-Jan et al. Assessing risk of COVID-19 reinfection and complications in adults treated with stimulant medications: A retrospective study using electronic health records. Medical Research Archives, [S.l.], v. 12, n. 9, sep. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5807>. Date accessed: 23 nov. 2024. doi: https://doi.org/10.18103/mra.v12i9.5807.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 12 No 9 (2024): Vol 12 No 9 (2024): September ISSUE, Issue 9, VOl.12
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Magnúsdóttir I, Lovik A, Unnarsdóttir AB, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. Lancet Public Health. 2022;7(5):e406-e416. doi:10.1016/S2468-2667(22)00042-1

2. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398-2405. doi:10.1038/s41591-022-02051-3

3. Perugi G, Pallucchini A, Rizzato S, et al. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD). Expert Opin Pharmacother. 2019;20(3):343-355. doi:10.1080/14656566.2018.1551878

4. Latronica JR, Clegg TJ, Tuan WJ, Bone C. Are Amphetamines Associated with Adverse Cardiovascular Events Among Elderly Individuals? J Am Board Fam Med JABFM. 2021;34(6):1074-1081. doi:10.3122/jabfm.2021.06.210228

5. Olfson M, Blanco C, Wang S, Greenhill LL. Trends in office-based treatment of adults with stimulants in the United States. J Clin Psychiatry. 2013;74(1):43-50. doi:10.4088/JCP.12m07975

6. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30-39. doi:10.1038/s41380-020-00880-7

7. Brumbaugh S, Tuan WJ, Scott A, Latronica JR, Bone C. Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: An observational cohort study. EClinicalMedicine. 2022;50:101524. doi:10.1016/j.eclinm.2022.101524

8. Geng J, Yu X, Bao H, et al. Chronic Diseases as a Predictor for Severity and Mortality of COVID-19: A Systematic Review With Cumulative Meta-Analysis. Front Med. 2021;8:588013. doi:10.3389/fmed.2021.588013

9. Peric S, Stulnig TM. Diabetes and COVID-19 : Disease-Management-People. Wien Klin Wochenschr. 2020;132(13-14):356-361. doi:10.1007/s00508-020-01672-3

10. Tuan WJ, Lennon RP, Zhang A, Macherla A, Zgierska AE. Risks of Severe COVID-19 Outcomes Among Patients With Diabetic Polyneuropathy in the United States. J Public Health Manag Pract JPHMP. 2022;28(6):674-681. doi:10.1097/PHH.0000000000001587

11. Yek C, Warner S, Wiltz JL, et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022;71(1):19-25. doi:10.15585/mmwr.mm7101a4

12. Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17:302. doi:10.1186/s12888-017-1463-3

13. Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol Oxf Engl. 2013;27(6):479-496. doi:10.1177/0269881113482532

14. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315(22):2424-2434. doi:10.1001/jama.2016.7602

15. Cosentino G, Conrad AO, Uwaifo GI. Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther. 2013;7:267-278. doi:10.2147/DDDT.S31443

16. Compton WM, Han B, Blanco C, Johnson K, Jones CM. Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States. Am J Psychiatry. 2018;175(8):741-755. doi:10.1176/appi.ajp.2018.17091048

17. Tuan WJ, Babinski DE, Rabago DP, Zgierska AE. Treatment with stimulants and the risk of COVID-19 complications in adults with ADHD. Brain Res Bull. 2022;187:155-161. doi:10.1016/j.brainresbull.2022.07.005

18. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLOS Med. 2015;12(10):e1001885. doi:10.1371/journal.pmed.1001885

19. Tuan WJ, Spotts H, Zgierska AE, Lennon RP. COVID-19 outcomes among adult patients treated with long-term opioid therapy for chronic non-cancer pain in the USA: a retrospective cohort study. BMJ Open. 2021;11(11):e056436. doi:10.1136/bmjopen-2021-056436

20. Piper BJ, Ogden CL, Simoyan OM, et al. Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PloS One. 2018;13(11):e0206100. doi:10.1371/journal.pone.0206100

21. Quinn PD, Chang Z, Hur K, et al. ADHD Medication and Substance-Related Problems. Am J Psychiatry. 2017;174(9):877-885. doi:10.1176/appi.ajp.2017.16060686

22. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc JAMIA. 2011;18(4):441-448. doi:10.1136/amiajnl-2011-000116

23. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry Off J World Psychiatr Assoc WPA. 2021;20(1):124-130. doi:10.1002/wps.20806

24. Heslin KP, Haruna A, George RA, et al. Association Between ADHD and COVID-19 Infection and Clinical Outcomes: A Retrospective Cohort Study From Electronic Medical Records. J Atten Disord. 2023;27(2):169-181. doi:10.1177/10870547221129305

25. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373. doi:10.4088/jcp.v69n0903

26. Chang Z, Quinn PD, Hur K, et al. Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. JAMA Psychiatry. 2017;74(6):597-603. doi:10.1001/jamapsychiatry.2017.0659

27. Ilieva IP, Farah MJ. Enhancement stimulants: perceived motivational and cognitive advantages. Front Neurosci. 2013;7:198. doi:10.3389/fnins.2013.00198

28. Hai T, Duffy HA, Lemay JA, Lemay JF. Impact of stimulant medication on behaviour and executive functions in children with attention-deficit/hyperactivity disorder. World J Clin Pediatr. 2022;11(1):48-60. doi:10.5409/wjcp.v11.i1.48

29. COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet Lond Engl. 2023;401(10379):833-842. doi:10.1016/S0140-6736(22)02465-5

30. Link-Gelles R, Levy ME, Natarajan K, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023;6(3):e232598. doi:10.1001/jamanetworkopen.2023.2598

31. Steele MK, Couture A, Reed C, et al. Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021. JAMA Netw Open. 2022;5(7):e2220385. doi:10.1001/jamanetworkopen.2022.20385